Raw Materials Management 2022-23 Insights
Raw Materials Management 2022-23 Insights
MANAGEMENT TEAM
Data User- Substantial
friendly Defects
security new moderation
processes product
Digitalisation availability Quality
benefits initiative
outcomes
Faster Waste
Fewer turnarounds Enhanced reduction
errors customisation
Timely
products availability
Lower
failures
SUPPLY CHAIN Emami is engaged in initiatives Highlights 2022-23 The Company utilised the reverse
auction platform (bidding) to
The Company leveraged business
intelligence through a dashboard,
Emami leveraged the power of
MANAGEMENT to reinforce the supply chain technology to support production capture the best freight rates. making it possible to analyse
Key Performance Indicators and
planning and distribution The Trip Tracker technology
around predictability, stability planning, driving supply chain
optimisation and efficiency.
helped the Company track
metrics on real-time leading to
informed decision-making.
shipments in real time and
and dependability The Company aims to minimise improve customer service.
Outlook
loss of sale to less than 1.5% of The Company managed vehicle The Company intends to
sales. placement orders online, moderate inventory, improve
Overview changes in consumer preferences The Company digitised its streamlining coordination its fill rate, ensure on-time
In the FMCG business, marked by and seasonal demands; there is a primary transport management between its logistics team and products delivery, enhance the
the manufacture of many products need to remain agile and flexible to system. transportation partners. role of planning, widen supply
and procurement of an even larger variations in resource availability, The Company’s digitised chain visibility, improve demand
costs, substitutes and quality. The Company maintained a
number of raw materials, there is a system for freight billing and forecasting, deepen digitisation,
Primary Freight Sales Ratio of
need to buy most at the lowest cost At Emami, we service the needs payment, streamlined the process moderate the freight sales ratio
~1% considered best-in-class for
in the shortest time – obviating an of more than 450 products and improved supply chain and enhance the role of ‘green’
cost-effectiveness.
inventory excess and stock out. through the timely aggregation of commercial efficiency. initiatives.
In such business, there is a hundreds of resources that need
premium on supply chain agility to be provided to proprietary and
and flexibility in adapting to third-party manufacturing facilities
INTELLECTUAL CAPITAL
How we are deepening
R&D research and
development at Emami
Emami’s
Emami’s Overview contemporary and differentiated
R&D function personal care products to address
cutting-edge Research
At Emami, of all the investments that
comprises unmet and emerging consumer and Development
we have made in our business in the
product or process last few decades, the most precious needs. The Company focuses on centres with high-end
development has been that of knowledge. multiple work streams like product sophisticated design and
today into what formulation, processing science, development equipment
consumers may Emami’s research and development consumer technical insights,
need tomorrow has not merely been directed at the and instruments are
competitive technology intelligence,
development of effective Ayurveda analytical development, perfumery located in
products, but also in cost moderation science, quality assurance and Mumbai & Kolkata
to enhance the consumer’s price- packaging development while
value proposition. The Company’s designing any product.
research and development
Addresses the Emami’s cutting-edge research and
needs to make competence has been captured in the
following priorities: development centres with high-end
products
sophisticated design and development
better One, Emami is committed to enhance equipment and instruments are
the accessibility of effective Ayurveda located in Mumbai and Kolkata. The
and the latest modern science-based Company has invested in talent-
differentiated products for consumers. based specialists who deal with
Addresses the Two, Emami is committed to cost- various aspects of product design extracting medicinal properties development and claim support of Science and Technology). It is
need to innovate
effectiveness, increasingly relevant and deployment through the NPD from herbs. studies. The Company also committed to quality outcomes
and create new journey from inception to roll out. conducted herb-drug interaction that ensure manufacturing of
when passing over increased costs to Emami’s Healthcare R&D
markets These functional experts comprise 99 studies on new drugs for lifestyle safe product in accordance with
consumers is challenging explores strengthening its
members (scientists with aggregate disorders., This is perhaps the World Health Organisation’s
Three, Emami is committed to experience of more than 978 years, 12 market responsiveness and
only Indian company having Good Manufacturing Practices
democratising its knowledge and PhD/MD holders and more than 46 improvements in existing
in-house facility to conduct (WHO-GMP) for Herbal
expertise leading to superior research post-graduates). functions. The Company
Addresses herb-to-drug interaction studies Medicines. By infusing quality
the need outcomes enabling cutting-edge strengthened its scientific
before introducing new products, and safety in its process, Emami
product launches collaborations (partnership with
to improve R&D in Healthcare validating its commitment to expects to provide reliable, safe
processes the Department of Biotechnology
Four, Emami prioritises governance, Emami leverages its extensive advance R&D capabilities and and effective healthcare products.
(DBT), Government of India,
compliance, data management knowledge and over a hundred create safe products.
New Delhi; Birla Institute of The Company has expanded the
systems and processes, strengthening years of experience in the Ayurveda Technology & Science (BITS), Emami is engaged in scope of safety and quality of
its positioning as a pioneer in healthcare sector (through its Pilani; Motilal Nehru National the development of two healthcare products by testing
innovation longstanding Zandu brand). Institute of Technology (MNIT) phytopharmaceutical drugs in contaminants like heavy metals
Addresses the The acquisition of Zandu was
need to enhance Allahabad, Prayagraj; Banasthali a new category (with Indian (mercury, cadmium, arsenic,
Emami’s approach to innovation complemented by Emami’s validated Vidyapeeth, Rajasthan; NSHM Council of Medical Research, and lead), aflatoxin and pesticide
Emami’s respect
for foresight Emami’s R&D team is engaged scientific expertise, making it possible Knowledge Campus, Kolkata, Ministry of Health and Family residues. All batches of every
in the development of a pipeline to develop therapies addressing etc) for complementing Emami’s Welfare, and the Department of healthcare product undergo
of ayurveda-based leading edge, lifestyle-related ailments and scientific capabilities for product Bio-Technology (DBT), Ministry testing for these contaminants.
Formulations Analytical
product in India. The R&D is promising results, demonstrating in conducting herb-drug
evaluating the application of this that patients had post-meal blood interaction studies was
Microbiology assay for other products as well. sugar levels within the desired recognised by the Central
range. Council for Research in
Fluctuating post-meal blood
Ayurvedic Sciences (CCRAS),
Pharmacognosy sugar level is a known but a The Bioassay laboratory
Ministry of AYUSH. The
and widely under-addressed problem generated efficacy data based
Company collaborated with
Phytochemistry among patients of diabetes. on Reverse Pharmacology,
CCRAS to provide data and
The R&D team conducted a ensuring the ‘scientifically tested’
insights related to herb-drug
ground-breaking study using the validation. The existing capacity
interaction for AYUSH-64,
R&D in Continuous Glucose Monitoring is limited to some therapeutic
recommended during the
healthcare (CGM) approach to assess the areas and to address this
pandemic. The team led the
effectiveness of Diabrishta, limitation, the R&D-Healthcare
project, sharing results with
a self-fermented polyherbal team is expanding capabilities to
CCRAS.
Bioassay preparation, as an adjuvant cover a wider therapeutic range.
Quality Control therapy for Type-II diabetes
Laboratory The Company’s expertise
and Assurance patients. The study yielded
Medical
Research Highlights 2022-23 currently in the launch pipeline. developing easy-to-swallow
Bio Resource
Development • The Company expanded the tablets with minimum effort.
• The CADE team isolated
bioassay immunity platform a compound Borapetol B • Following persistent
beyond conventional NK cell exclusively present in Tinospora multipronged efforts in the
Competitive strengths Pharmacognosy, Microbiology, Publications: Numerous peer- activity studies to TNF- and crispa, validating it as negative conservation and sustainable
Infrastructure: The Company Molecular Pharmacology, and reviewed articles were published IL-6 based studies. While most marker for Tinospora cordifolia. use of Biodiversity by captive
expanded its cutting-edge Biotechnology), resulting in a by team members in reputed companies are still focused on This intervention would help to and contract cultivation, Emami
research center, aimed at knowledge sharing platform. scientific journals; few scientists NK cell activity, the Company ensure consistent quality and got a special recognition – the
developing innovative products were invited to serve on the recognised the need to expand its enhanced safety of Giloy. only corporate from the AYUSH
Corporate Analytical Design
across dosage forms. editorial boards of international research to comprehend complex stream to get a representation in
Excellence: The Company’s • The Company has launched
journals. immunity mechanism better. G-20 Research and Innovation
Bioassay lab: This laboratory state-of-the-art Corporate SENIORZ product range after
Analytical Design Excellence Bio-resources: The Bio- The proposed approach can be Initiative Gathering in Dibrugarh
has accelerated efficacy studies, used in claims substantiation. in depth analysis of the special
(CADE) laboratory has isolated resources Development and Itanagar on 24-25th
providing scientific validation, needs of the persons in silver
more than 120 marker Department promoted the • The Company launched over 20 March 2023 by Department
substantiating claims through range. R&D has applied unique
compounds for standardizing cultivation of medicinal plants products through e-commerce of Biotechnology, Ministry of
data analysis. In 2022-23, the pharmaceutical technologies
raw materials and finished through captive and contract and other marketing platforms. Science and Technology on
laboratory performed over 5000 probably for the first time in any
products, enhancing quality farming. Despite pandemic Various new products are ‘Circular Bio-economy’, drawing
Bioassays (enzymatic, non- Ayurvedic product in India by
control and quality assurance related challenges, the Company participation from 35 countries.
enzymatic and cell-based assays)
to support the health benefit capabilities. maintained a sustainable supply
claims. of quality herbs and resources
Accreditations: The Company’s
(tulsi, ginger, guduchi and
Scientific experience: The R&D centre received accreditation
others).
Company invested in a cross- from NABL, Ministry of AYUSH Introduced a new scientific claim for Zandu Kesari Jivan
functional teams (Ayurveda, and the Department of Scientific
Before: The claim was updated from ‘Improves immunity’ to ‘2x
Chemistry, Pharmaceutics, Industrial Research.
immunity’
After: Zandu Kesari Jivan now claims an ‘anti-age action’
R&D initiatives developed (including SENIORZ To strengthen the relevance of based on a newly developed assay by the Company’s bioassay
The R&D team introduced over Pain Relief Oil, SENIORZ Daily the claim the Bioassay laboratory laboratory.
30 products and is focused on Health Booster Syrup, SENIORZ developed a non-enzymatic
advancing approximately 150 Bone Strength Tablet and assay to establish the Advanced
New Product Development SENIORZ Complete Joint Expert Glycation End products (Anti-
Projects across ethical marketing, Tablet) addressing the elderly AGEs) assay to support the action
OTC and generic categories. with a unique pharmaceutical of Kesari Jivan. Emami is the first
technology application to company to conduct studies and
A SENIORZ product range was develop easy-to-swallow tablets. make this claim on an Ayurvedic
HUMAN CAPITAL
HUMAN How we have deepened
RESOURCES Knowledge Capital at Emami
Wah! Awards - Employee Reward Programme Independence Day celebration at Emami’s Pacharia unit
Governance review
SOCIAL &
RELATIONSHIP CAPITAL Emami Board’s enhanced focus. The Company’s trust and confidence with an eye
independence Board comprised the following on corporate performance and
The Emami Board comprises committees: accountability
50% Independent Directors, • Audit Committee • Review of compliances as per
who bring a dispassionate, • Nomination and Remuneration listing regulations
independent and diverse Committee • Enhancement and protection of
Emami: Pioneering judgment to the strategic table. • Stakeholders’ Relationship
Committee
shareholder value
• Implementation of business
excellence through ethical Emami Board’s diversity
Emami’s Board diversity
• Corporate Social Responsibility responsibility and sustainability
report system
Committee
governance harnesses differences in
knowledge, skills, regional / • Risk Management Committee Compliance control
industry experience, cultural / • Corporate Governance mechanism
geographical backgrounds, age, Committee (also overseeing the • A defined compliance matrix
and genders. There are 3 women responsibility of ESG Initiatives) with responsibility specified for
Directors on the Board. • Share Transfer Committee each statute for each business
Overview invested proactively in is managed. The spirit of
digitalisation and demonstrated governance balances the • Finance Committee place
Emami is committed to credible
an extensive commitment to interests of all stakeholders
Key expertise areas of the • Digitalisation of the control
governance that enhances Board of Directors- • Buyback Committee
regulatory compliances. (shareholders, management, system
its respect as a responsible • Management of complex
corporate citizen. The Company In view of this, governance customers, suppliers, financiers,
business processes
Emami Board oversight • Defined performers & reviewers
is led by a strong Board; it has at Emami comprises rules, government and community), Diverse Emami Board • Monthly statutory compliances
making governance integral to • Visioning, Strategic Planning and
outlined standard operating protocols and processes M&A committees carry out defined are updated in the system from
protocols for most functions, by which the Company the Company’s existence. roles. The Board supervised all locations via units, depots and
• Consumer Insights, Innovation &
committees and was responsible offices
Marketing
for their actions. The Board also • Review and checking of a
• Financial & Risk Management oversaw safety performance, composite report of statutory
• Supply Chain Management validating a safety-first culture.
External environment alliances, trade consolidation and transparent disclosures and compliances by the Legal Team &
• Governance and Regulatory Internal Auditor
and governance at integration. This environment effective Board governance.
Requirements Responsibilities delegated
Emami presents opportunities; there is a The Company deepened its
by the Board
Emami operates in an
premium on speed, innovation governance framework, policies Emami Board committees
and risk management. Emami’s and disclosures; it monitored • Review of corporate governance
environment, marked by Emami Board committees practices
strategy is directed to enhance and evaluated outcomes, cover a range of subjects with
economic impacts, demographic
value across the medium to contemporising relevance. • Building an environment of
trends and technology
long-term. Emami outlined
advancements with a focus on
INTERNATIONAL into a dynamic global citizen growing in the international across clusters (SAARC, GCC/
markets, warranting a different Middle East, Russia/CIS, SEA,
BUSINESS Overview
Around 25 years ago, Emami
The Company has come a long
way with offices in Dubai, Moscow,
approach. The Company
responded with a different
Sub-Saharan Africa etc.) and sales
are sustained under enduring
mindset and the result is that the Emami brands or the acquired
sensed an opportunity for its Dhaka, Colombo and Kathmandu,
international business has grown, Creme21 brand.
brands and products in the coupled with own-cum-third
provides direct employment to
international markets, venturing party manufacturing units in
into exports through a distribution Bangladesh, UAE, Germany, Sri
network across 70 countries. Lanka and Thailand, reinforced by
exports from India.
Brand performance in the consumers. More than ~100mn Aloe Vera. With ~ 12mn units
international markets units of Navratna are sold across sold annually, the brand grew in
Boroplus: The brand retails international geographies. In mid-teen percentage during the
around 15mn units across 2022-23, the brand grew more last year.
international geographies, than 40%. Fair & Handsome / Smart &
contributing ~ 16% of overall 7 Oils in 1: The brand was Handsome: In two decades,
International sales. In 2022-23, introduced in the international the brand, launched as male
the brand grew by more that market around 2015 and now whitening, has evolved into
50% in topline over the previous commands a large revenue share an advanced male grooming
year despite challenging market compared to the Indian market. brand. With sales of 12mn units,
SAARC & SEA MENAP CIS & Eastern Europe Africa & Others the brand registered a growth
conditions. New offerings under hair oils
made in recent years comprise of 25%. In 2022-23 the brand
Navratna: Has moved beyond was repositioned as Smart &
traditional red cooling oil Black seed, Cactus, Shea Butter,
Handsome in international
catering to the needs of different Castor, Almond, Coconut and
geographies.
Creme21: This iconic German 23, the brand grew in the mid- Fast Relief and Zandu brands.
brand was acquired in 2019 teen percentages. These offerings are leading the
and become an integral part of Topical pain management: categories / markets they operate
Emami’s brands. Today ~5 mn Includes balms, ointments and in. Today, ~ 40mn units are sold
units are sold annually in the sprays under the Menthoplus, annually with mid-single digit
international markets. In 2022- sales growth.
EMAMI’S ROLE AS
A RESPONSIBLE CORPORATE CITIZEN
We have engaged in responsible
CSR community development Emami’s various CSR
initiatives in the field of
through various initiatives and education
activities
Overview Emami’s CSR policy
Emami’s CSR activities focus on The CSR policy of Emami aligns with
holistic societal development. The the Company’s philosophy of fulfilling
Focus on its responsibility as a corporate
Company’s CSR programmes are
under-
designed by a Board-level committee, citizen with its business ethics,
addressed
areas highlighting the Company’s social while undertaking initiatives for the
development priority. By partnering well-being of under-privileged and
civil society and NGOs, Emami has deprived sections of the society.
widened its CSR impact.
CSR commitment, 2022-23
Enhanced Rajkumar Goenka, Patron-CSR
Emami and CSR During 2022-23, the Company
effectiveness
derived Emami has implemented social allocated H10.48 Cr for CSR initiatives
through NGO interventions across the country. across education & skill development,
partnerships Its Corporate Social Responsibility health, water & sanitation, and social
initiatives are designed around United upliftment engagements. Of the Initiatives Nanhi Saraswati Girl Child Education
allocated corpus, H2.60 Cr was spent Student Support Program: Provided Support Program: Provided learning
Nations’ Sustainable Development
on education and skill development, scholarships, financial aid and opportunities to meritorious as well
Goals, with an emphasis on advancing
H2.97 Cr on health, water and education materials support to 124 as needy girl child students from
Allocation of a education, skill development and
sanitation and H4.14 Cr on social uplift. underprivileged students for their economically weaker sections.
sizable part of the healthcare.
surplus towards studies and distributed textbooks to Project Udayan Care – Shalini
community 500+ needy students. Fellowship Program: Provided
development
Education Infrastructure Support: support for academic excellence
Provided infrastructure support to and personality development of
Project
various school/educational institutions 50 Shalinis - girl students from
PADHO INDIA PADHO for better education facilities. underprivileged sections of the society.
Individual attention, counselling and
Ekal Vidyalaya: Provided support to grooming through regular mentoring
This initiative promotes holistic education support for Friends of Tribal Society to operate 75 programmes were provided for their
the children and students from socially and economically one-teacher schools, benefitting 1131 overall mental and moral development.
downtrodden sections of the society. students.
Digital education in rural areas: Smart
Overview sector. This project provides After School Support Program: classrooms were set up at Haripal
With a strong belief in education students, schools and educational Provided after-school coaching Centre of Emami Foundation for rural
being the driver of socio-economic institutions with necessary support to 170+ students at Emami students to access the best teachers
progress, the project was initiated learning resources and support. Foundation CSR centres in Kolkata and from Kolkata.
to promote a holistic approach Deserving students from financially Haripal.
towards supporting the education marginalised families are granted
scholarships and study grants.
Project supplements in and around chosen artists were provided Animal welfare: The Company
factory units and through Emami the opportunity to live and supported veterinary clinics for
Project
Diabetes care centre: It up a research and rehabilitation benefitting 70,000+ beneficiaries
Addresses the need to grow the • Operating in line with • Monitoring and containing
CAPITAL footprint
BRANDS
AND MARKETING
AWARDS
BoroPlus felicitated
as one of the ‘Iconic Software Defined
Brands of India’
Network (SDWAN)
at the 5th edition
of ‘The Economic implementation project
Times Iconic Brands selected as a winner
of India’ at the 3rd Quantic
India Technology
Excellence Awards 2023
Received the ET Bengal Corporate Award (ETBCA) under the category of
2022 for ‘Best Financial Performance’ among ‘Best Infrastructure
companies with a turnover of over H1500 Cr Transformation in
FMCG Industry’
INDIVIDUAL RECOGNITION
Mr Harsha V. Agarwal,
Vice Chairman &
Managing Director,
elected as Vice President
of Federation of Indian
Chambers of Commerce
and Industry – FICCI
Businessworld,
featured Ms.
Priti A. Sureka, Mr Prashant Goenka, Wholetime
Co-Founder and Chairman,
Wholetime Director Director, felicitated with the
Mr. R. S. Goenka conferred with the prestigious
in its Special Issue Entrepreneur of the Year – 2022
“Banga Bibhusan” award from the State
on ‘Most Influential Award (Consumer Category) in
Government of West Bengal.
Women’ of India. Dubai by the ITP Media Group at
its 14th Annual CEO Middle East
Awards.
98 | Integrated Annual Report 2022-23
Corporate Overview Statutory Reports Financial Statements
Directors’ Report
It gives me great pleasure to share with you the During the year under review, the newly acquired
performance of your Company along with audited brand Dermicool was integrated from April 1,2022
accounts for the financial year ended March 31, and Helios Lifestyle which operates under the
2023. In compliance with the applicable provisions brand “The Man Company” became the Company’s
of Companies Act, 2013, (“the Act”) and the Securities subsidiary with effect from July 1,2022
and Exchange Board of India (Listing Obligations
Further, the Company launched more than 20
and Disclosure Requirements) Regulations, 2015
products in FY23, with a majority being digital first
(“SEBI Listing Regulations”), this report covers the
launches on its D2C portal Zanducare.
financial results and other developments during the
financial year from April 1, 2022 to March 31, 2023. The Company’s Modern Trade and E-Commerce
channels continued to grow strongly during the
1. Operational Review year. While Modern Trade grew by 37%, it increased
its contribution to domestic business by 220 bps
During the year under review, the demand
to 9.3%. E-Commerce sales also increased by 82%
environment continued to remain challenging with
increasing its contribution to domestic business by
the FMCG sector impacted by an unprecedented
400 bps to 9.3%.
inflation leading to rural slowdown, liquidity
pressure and subdued consumer sentiment. Over the past 2 years, the Company embarked on
a journey under “Project KHOJ” to double its rural
The year also witnessed significant corrections in
coverage adding ~20,000 rural towns & villages,
two categories - pain management and Healthcare
taking its overall footprint to 52,000 such rural
– that enjoyed a high revenue base during the
villages. In FY24, the Company plans to add further
pandemic year. This, along with high input costs
8,000 villages to reach its target of 60,000 villages.
and favourable portfolio mix last year impacted
This rural expansion is getting digitized and
margins.
geocoded at the same time giving the organization
Further, a warmer winter season impacted the sales a wealth of rural retail level behaviour and buying
of winter portfolio in Q3FY23 and unseasonal rains patterns to ensure higher service levels.
across the country impacted the loading of summer
The Company’s International business continued
products in Q4FY23. In the given macroeconomic
its stellar performance growing by 20% in FY23
environment, the Company posted Revenues of
despite of high inflation and several key markets
Rs. 3,406 cr. which was 7% higher than the previous
facing challenges like currency depreciation in
year.
Bangladesh, economic crisis in Sri Lanka, forex
Most of the Company’s major brands increased their & liquidity crisis in Nepal and ongoing political
household penetration levels during the year under conflict in CIS countries etc. This was made possible
review. Sustained interventions and marketing only on account of strong brand building activities
efforts ensured that they further cemented their across key geographies.
leadership positions in their respective categories.
During the financial year, Gross Margins at 64.7%
Major brands like Navratna grew by 6%, Male
declined by 160 bps on account of higher input
Grooming range grew by 4%, 7 Oils in One grew
costs and favourable portfolio mix in the base year.
by 10% and BoroPlus and Kesh King grew by 1%
EBIDTA margins excluding strategic investments at
respectively.
26.7% are close to pre-COVID levels and including
Pain Management range and Healthcare range, strategic investments, they stand at 25.2%. PAT
being COVID contextual categories witnessed before MAT credit entitlement of earlier years at Rs.
corrections during the year, however on a 4 year 627 Cr grew by 4% over previous year and by 20% on
CAGR basis, Pain Management range grew by 6% a 4 year CAGR basis.
and Healthcare range grew by 8%.
Financial results
(Rs. lacs)
Particulars Standalone Consolidated
2022-23 2021-22 2022-23 2021-22
Operating income 2,90,683 2,86,687 3,40,573 3,19,203
Profit before interest, depreciation and taxation 82,544 1,02,012 93,168 1,04,762
Interest 373 345 739 507
Depreciation and amortisation 21,538 32,761 24,725 33,478
Profit Before Tax and Exceptional Items 60,633 68,906 67,704 70,777
Exceptional Items - - - 518
Profit before taxation 60,633 68,906 67,704 70,259
Less: Provision for taxation
- Current tax 11,077 12,209 12,678 13,539
- Deferred tax ( net ) 760 438 90 404
-MAT credit entitlement (8,554) (28,809) (8,554) (28,809)
Profit after taxation 57,350 85,068 63,490 85,125
Non-controlling interest - - (1216) (232)
Profit after minority interest 57,350 85,068 64,706 85,357
Share of profit/(loss) of associate - - (750) (1,458)
Profit for the year 57,350 85,068 63,956 83,899
Balance brought forward 1,16,684 67,182 1,15,830 67,646
Profit available for appropriation 1,74,034 1,52,250 1,79,786 1,51,545
Appropriation
Effects of adoption of new accounting standard , i.e, - -
Ind AS 115
Interim dividend 35,292 35,561 35,292 35,561
Corporate dividend tax - -
Re-measurement of net defined benefit plans (net of 72 5 -29 154
tax)
Acquisition of Non-controlling interests - - 515 -
Balance carried forward 1,38,670 1,16,684 1,44,008 1,15,830
Total 1,74,034 1,52,250 1,79,786 1,51,545
98 Emami Limited
Corporate Overview Statutory Reports Financial Statements
March 31, 2023, the Company earned revenues 12. Consolidated financial statements
worth Rs. 1,958 lacs (previous year Rs. 1,772 lac) and The consolidated financial statements, prepared in
Profit/(loss) after tax of Rs. (1,133) Lacs [previous year accordance with (Ind AS 110) consolidated financial
Rs. (495) lacs]. statements, form part of this Report. The net worth
of the consolidated entity as on March 31, 2023,
Helios Lifestyle Private Limited
stood at Rs. 2,30,280 lacs as against Rs. 2,07,659 lacs
Helios Lifestyle Private Limited has become a
at the end of the previous year.
subsidiary of Emami Limited w.e.f 1st July, 2022.
It is engaged in online male grooming sector and 13. Compliance with Secretarial
during the financial year ended March 31, 2023, Standards of ICSI
earned revenues worth Rs. 11,500 lacs (previous
year Rs. 8,278 lacs) and a profit/(loss) after tax of Rs. The Ministry of Corporate Affairs has mandated
(2,204) lacs {previous year Rs. (2,701) lacs}. SS-1 and SS-2 with respect to board meetings and
general meetings respectively. The Company has
Associate companies ensured compliance with the same.
Tru Native F&B Pvt Ltd. 14. Transfer of Unclaimed Dividend and
The Company made strategic investment in Tru
Native F&B Pvt Ltd on March 5, 2022. The current
Unclaimed shares
strategic investment in Tru Native F & B Pvt. Ltd., The details relating to unclaimed dividend and
is equivalent to 20.65% of its paid up capital on unclaimed shares forms part of the Corporate
fully diluted basis. Tru Native is a smart nutrition Governance Report forming part of this report.
company dedicated to empowering health and
fitness enthusiasts with affordable and healthy food 15. Auditors and Auditors’ Reports
& nutrition options.
Statutory auditor
During the financial year ended March 31, 2023, Your Company’s Statutory Auditors, M/s. S.
the Company earned revenues worth Rs 324 lacs R. Batliboi & Co. LLP, Chartered Accountants
(Previous year Rs. 62 lacs) and a profit/(loss) after tax (FRN :301003E/E300005), were re-appointed as the
of Rs. (421) lacs (previous year Rs. (117) lacs). Statutory Auditors of the Company for a second
term of consecutive five years from the conclusion
Cannis Lupus Services India Pvt Ltd.
of 39th Annual General meeting till the conclusion of
The Company has made strategic investment in
44th Annual General Meeting.
Cannis Lupus Services India Pvt Ltd on 21st July,
2022. The current strategic investment in Cannis The Auditor’s report on the standalone &
Lupus Services India Pvt. Ltd. is equivalent to 30% consolidated financial statement of the Company
of its paid up capital on fully diluted basis. Cannis for the financial year ended on March 31, 2023 does
Lupus is a pet-care start- up offering Ayurvedic / not contain any qualification, reservation or adverse
herbal remedies for pets under the brand “Fur Ball remark or disclaimer.
Story”.
Secretarial auditor
During the financial year ended March 31, 2023,
the Company earned revenues worth Rs 46 lacs Pursuant to the provisions of Section 204 of the
(Previous year Rs, 22 lacs) and a profit/(loss) after tax Companies Act, 2013 read with the Companies
of Rs. (123) lacs (previous year Rs. 5 lacs). (Appointment and Remuneration of Managerial
Personnel) Rules, 2014, the Company has appointed
M/s MKB & Associates, Practicing Company
10. Public Deposits Secretaries (FRN: P2010WB042700) as its secretarial
The Company has not accepted any public deposits auditor to undertake the Secretarial Audit for
covered under Chapter V of the Companies Act, FY 2022-2023.
2013 read with the Companies (Acceptance of
Deposits) Rules, 2014. The secretarial audit report certified by the
secretarial auditors, in the specified form MR-3
is annexed herewith and forms part of this report
11. Non-convertible debentures (Annexure I). The secretarial audit report does not
The Company did not issue any non-convertible contain any qualifications, reservations or adverse
debentures during the financial year 2022-23. remarks. Furthermore, the Secretarial Auditor M/s
MKB & Associates, Practicing Company Secretaries,
None of the Directors of the Company is disqualified about the business and operations of the Company
for being appointed/re-appointed as Director, as from time to time.
specified under section 164(2) of the Companies Act,
The Directors are also updated on the changes
2013 and Rule 14(1) of the Companies (Appointment
in relevant corporate laws relating to their roles
and Qualification of Directors) Rules, 2014.
and responsibilities as Directors. The details
A brief resume of the Directors proposed to be re- of the Board familiarisation programme for
appointed is provided in the Notice of the Annual the Independent Directors can be accessed
General Meeting forming part of the Annual report. at:[Link]
p d f / E m a m i L t d Fa m i l i a r i s a t i o n P r o g r a m m e
The existing Company Secretary, Shri A.K. Joshi’s term
[Link]
is going to complete at the end of closing hours of May
31, 2023 (on his retirement). Upon recommendation
of the Nomination and Remuneration Committee, the 23. Performance evaluation
Board of Directors has appointed Shri Sandeep Kumar Pursuant to the provisions of Section 178 of
Sultania as Company Secretary & Compliance Officer the Companies Act, 2013 read with rules made
of the Company with effect from June 01, 2023. thereunder, Regulation 17(10) of the SEBI Listing
Regulations and the Guidance note on Board
20. Business Responsibility and evaluation issued by SEBI vide its circular dated
January 5, 2017, the Company has framed a policy
Sustainability Report
for evaluating the annual performance of its
As required under Regulation 34 of SEBI Listing Directors, Chairman, the Board as a whole, and the
Regulations 2015, the Business Responsibility various Board Committees. The Nomination and
and Sustainability Report of the Company for the Remuneration Committee of the Company has laid
financial year ended March 31, 2023 is attached as down parameters for performance evaluation in the
part of the Annual Report. policy.
21. Dividend Distribution Policy The Board also evaluated the performance of each
of the Directors, the Chairman, the Board as a whole
The Company has formulated a Dividend and all committees of the Board. The process of
Distribution Policy, which has been displayed on the evaluation is carried out in accordance with the
website of the Company, [Link] Board Evaluation Policy of the Company and as
investor-info/pdf /Dividend_Distribution_Policy_ per the criteria laid down by the Nomination &
[Link]. Remuneration Committee.
22. Board induction, training and 24. Number of meetings of the Board
familiarisation programme for The Board of Directors held five meetings during
Independent Directors the year on May 13, 2022, July 29, 2022, November
Prior to the appointment of an Independent 11 , 2022, February 3, 2023 and March 24, 2023. The
Director, the Company sends him/her a formal maximum gap between any two meetings was less
invitation along with a detailed note on the profile of than 120 days, as stipulated under SEBI’s Listing
the Company, the Board structure and other relevant Regulations, 2015. The details of Board Meetings
information. At the time of appointment of the held and attendance of Directors are provided in the
Director, a formal letter of appointment which inter Report on Corporate Governance forming part of
alia explains the role, functions, and responsibilities this report.
expected of him/her as a Director of the Company is
given. The role, functions, and responsibilities of the 25. Committees of the Board
Director are also explained in detail and informed
The Company has constituted/reconstituted
about the various compliances required from him/
various Board-level committees in accordance with
her as a Director under the various provisions of the
the requirements of the Companies Act, 2013 and
Companies Act 2013, SEBI Listing Regulations, 2015,
SEBI Listing Regulations, 2015. The Board has the
SEBI (Prohibition of Insider Trading) Regulations,
following committees as under:
2015, the Code of Conduct of the Company and
other relevant regulations. I. Audit Committee
A Director, upon appointment, is formally inducted II. Nomination and Remuneration Committee
to the Board. In order to familiarise the Independent
III. Share Transfer Committee
Directors about the various business drivers,
they are updated through presentations at Board IV. Stakeholders Relationship Committee
Meetings about the performance and financials of
V. Finance Committee
the Company. They are also provided presentations
32. Management discussion and analysis philosophy against discrimination and sexual
and Corporate Governance Report harassment including awareness programme,
which included creation and dissemination of
As per Regulation 34(3) read with Schedule V of
comprehensive and easy-to-understand training
the SEBI Listing Regulations 2015, Management
and communication material.
Discussion Analysis, Corporate Governance
Practices followed by your Company, together
with a certificate from the Company’s auditors 35. Details of significant and material
confirming compliance of conditions of Corporate orders passed by regulators/courts/
Governance are an integral part of this Report. tribunals
There was no instance of any material order passed
33. Risk management system by any regulators/courts/tribunals impacting the
The Company has developed and implemented going concern status of the Company.
a risk management policy which is periodically
reviewed by the management. The system also 36. Other Confirmations
complies with the requirements laid down under During the year under review, the Company filed an
the ISO 31000: 2018 norms. application before the Hon’ble National Company
In accordance with Regulation 21 of SEBI Listing Law Tribunal, Mumbai Bench (NCLT) to initiate
Regulations, 2015, the enterprise risk management corporate insolvency resolution process under
policy of the Company, which has been duly approved the Insolvency and Bankruptcy Code, 2016 (Code)
by the Board, is reviewed by the Risk Management against Future Retail Limited, C.P (IB) No. 638 of
Committee, Audit Committee and the Board on 2022 for recovery of dues which is pending as on
a quarterly basis. The risk management process 31st March, 2023. Further, there are no instances of
encompasses practices relating to identification, one-time settlement with any Bank or Financial
assessment, monitoring and mitigation of various Institutions.
risks to key business objectives. Besides exploiting
the business opportunities, the risk management 37. Directors’ Responsibility Statement
process seeks to minimise adverse impacts of risk to Pursuant to the requirements laid down under
key business objectives. Section 134(5) of the Companies Act, 2013, with
respect to the Directors’ Responsibility Statement,
34. Prevention of sexual harassment the Directors confirm that:
at workplace I. In the preparation of the annual accounts for
Your Company is committed to provide a work the year ended March 31, 2023, the applicable
environment which ensures that every woman accounting standards have been followed and
employee is treated with dignity, respect and no material departures have been made;
equality. There is zero-tolerance towards sexual
harassment and any act of sexual harassment II. The Directors have selected such accounting
invites serious disciplinary action. policies and applied them consistently and
made judgments and estimates that are
As per the requirements of the Sexual Harassment of reasonable and prudent so as to give a true and
Women at the Workplace (Prevention, Prohibition fair view of the state of affairs of the Company
and Redressal) Act, 2013 (POSH), your Company has as on March 31, 2023, and of the profit of the
established a policy to prevent sexual harassment Company for the year ended on that date;
of its women employees. The policy allows every
employee to freely report any such act with the III. The Directors have taken proper and sufficient
assurance of prompt action to be taken thereon. The care for the maintenance of adequate
policy lays down severe punishment for any such accounting records in accordance with the
act. The Company has complied with provisions provisions of the Companies Act, 2013 for
relating to the constitution of internal complaints safeguarding the assets of the Company and
committee under POSH. During the year under for preventing and detecting fraud and other
review, the company has received one complaint irregularities;
under the Sexual Harassment of Women at the IV. The annual accounts were prepared on a going
Workplace (Prevention, Prohibition and Redressal) concern basis;
Act, 2013 and it has been resolved. There is no
pending case at any of the business places of the V. The Directors have laid down effective internal
Company. financial controls to consistently monitor the
affairs of the Company and ensured that such
Several initiatives were undertaken during the internal financial controls were adequate and
year to demonstrate the Company’s zero tolerance operating effectively;
38. Acknowledgements
Your Directors would like to acknowledge and For and on behalf of the Board
place on record their sincere appreciation of all
stakeholders – shareholders, bankers, dealers, R.S. Goenka
vendors and other business partners for the Place: Kolkata Chairman
unstinted support received from them during Date: May 25, 2023 (DIN – 00152880)